Secondary cerebro-cerebellar and intracerebellar dysfunction in cerebellar mutism syndrome
CONCLUSIONS: The functional abnormalities we identified are notably upstream of where causal surgical injury is thought to occur, indicating a secondary phenomenon. The VM-PFC is involved in several functions that may be relevant to the symptomatology of CMS, including emotional control and motor learning. We hypothesize that these abnormalities may reflect maladaptive learning within the cerebellum consequent to disordered motor and limbic function by the periaqueductal grey and other critical midbrain targets.PMID:38581226 | DOI:10.1093/neuonc/noae070 (Source: Cancer Control)
Source: Cancer Control - April 6, 2024 Category: Cancer & Oncology Authors: Samuel S McAfee Giles Robinson Amar Gajjar Nicholas S Phillips Silu Zhang Ping Zou Stinnett Ranganatha Sitaram Darcy Raches Heather M Conklin Raja B Khan Matthew A Scoggins Source Type: research
Pediatric neurosurgical medulloblastoma outcomes in La Paz, Bolivia: How a Lower Middle-Income Country (LMIC) institution in South America compares to the United States
ConclusionsPediatric neurosurgical medulloblastoma outcomes at the Children ’s Hospital of La Paz, Bolivia are significantly inferior to that of a generalized US experience. Future research is required to identify institution- and country-specific initiatives to improve discrepancies between institutions in LMICs in South America compared to HICs. (Source: Journal of Neuro-Oncology)
Source: Journal of Neuro-Oncology - April 2, 2024 Category: Cancer & Oncology Source Type: research
Clinical and histopathological spectrum of cranial small round cell tumors: An experience from a tertiary care center
CONCLUSIONS: SRCTs have a variable age of presentation. Their incidence in CNS is low as compared to other organ systems. On light microscopy, the histopathology of these lesions is overlapping, posing a great diagnostic dilemma for the pathologist. The use of ancillary techniques like immunohistochemistry helps in arriving at the correct diagnosis. Treatment strategy and tumor prognosis also vary along the entire spectrum of SRCT, thus making exact characterization essential for proper management.PMID:38554327 | DOI:10.4103/jcrt.jcrt_383_22 (Source: Cell Research)
Source: Cell Research - March 30, 2024 Category: Cytology Authors: Pooja Gupta Fouzia Siraj K B Shankar Manish Rawat Dipanker S Mankotia Vivek Yadav Amit Dagar Source Type: research
GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma
CONCLUSIONS: Our experimental data indicate the feasibility of CAR.GD2 T-cell therapy. A phase I/II clinical trial will be conducted to evaluate the safety and therapeutic efficacy of CAR.GD2 therapy in high-risk MB patients.PMID:38551501 | DOI:10.1158/1078-0432.CCR-23-1880 (Source: Cell Research)
Source: Cell Research - March 29, 2024 Category: Cytology Authors: Roselia Ciccone Concetta Quintarelli Antonio Camera Michele Pezzella Simona Caruso Simona Manni Alessio Ottaviani Marika Guercio Francesca Del Bufalo Maria Cecilia Quadraccia Domenico Orlando Stefano Di Cecca Matilde Sinibaldi Mariasole Aurigemma Laura Ia Source Type: research
GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma
CONCLUSIONS: Our experimental data indicate the feasibility of CAR.GD2 T-cell therapy. A phase I/II clinical trial will be conducted to evaluate the safety and therapeutic efficacy of CAR.GD2 therapy in high-risk MB patients.PMID:38551501 | DOI:10.1158/1078-0432.CCR-23-1880 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 29, 2024 Category: Cancer & Oncology Authors: Roselia Ciccone Concetta Quintarelli Antonio Camera Michele Pezzella Simona Caruso Simona Manni Alessio Ottaviani Marika Guercio Francesca Del Bufalo Maria Cecilia Quadraccia Domenico Orlando Stefano Di Cecca Matilde Sinibaldi Mariasole Aurigemma Laura Ia Source Type: research
GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma
CONCLUSIONS: Our experimental data indicate the feasibility of CAR.GD2 T-cell therapy. A phase I/II clinical trial will be conducted to evaluate the safety and therapeutic efficacy of CAR.GD2 therapy in high-risk MB patients.PMID:38551501 | DOI:10.1158/1078-0432.CCR-23-1880 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 29, 2024 Category: Cancer & Oncology Authors: Roselia Ciccone Concetta Quintarelli Antonio Camera Michele Pezzella Simona Caruso Simona Manni Alessio Ottaviani Marika Guercio Francesca Del Bufalo Maria Cecilia Quadraccia Domenico Orlando Stefano Di Cecca Matilde Sinibaldi Mariasole Aurigemma Laura Ia Source Type: research
GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma
CONCLUSIONS: Our experimental data indicate the feasibility of CAR.GD2 T-cell therapy. A phase I/II clinical trial will be conducted to evaluate the safety and therapeutic efficacy of CAR.GD2 therapy in high-risk MB patients.PMID:38551501 | DOI:10.1158/1078-0432.CCR-23-1880 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 29, 2024 Category: Cancer & Oncology Authors: Roselia Ciccone Concetta Quintarelli Antonio Camera Michele Pezzella Simona Caruso Simona Manni Alessio Ottaviani Marika Guercio Francesca Del Bufalo Maria Cecilia Quadraccia Domenico Orlando Stefano Di Cecca Matilde Sinibaldi Mariasole Aurigemma Laura Ia Source Type: research
GD2-targeting CAR T-cell therapy for patients with GD2+ medulloblastoma
CONCLUSIONS: Our experimental data indicate the feasibility of CAR.GD2 T-cell therapy. A phase I/II clinical trial will be conducted to evaluate the safety and therapeutic efficacy of CAR.GD2 therapy in high-risk MB patients.PMID:38551501 | DOI:10.1158/1078-0432.CCR-23-1880 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - March 29, 2024 Category: Cancer & Oncology Authors: Roselia Ciccone Concetta Quintarelli Antonio Camera Michele Pezzella Simona Caruso Simona Manni Alessio Ottaviani Marika Guercio Francesca Del Bufalo Maria Cecilia Quadraccia Domenico Orlando Stefano Di Cecca Matilde Sinibaldi Mariasole Aurigemma Laura Ia Source Type: research
Case report: Therapy-related myeloid neoplasms in three pediatric cases with medulloblastoma
ConclusionsThis report highlights the potential association between genetic predisposition syndromes and the development of therapy-related myeloid neoplasms in pediatric medulloblastoma survivors. It underscores the importance of surveillance for hematological abnormalities among such patients. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - March 26, 2024 Category: Cancer & Oncology Source Type: research
GSE103824 Olig2 targetome in SHH subgroup of medulloblastoma
Contributor : Wen-Chi YinSeries Type : Genome binding/occupancy profiling by high throughput sequencingOrganism : Mus musculusSeveral basic helix-loop-helix (bHLH) transcription factors are upregulated in Sonic Hedgehog subgroup of medulloblastoma (SHH MB). Olig2, a neural bHLH transcription factor known to regulate differentiation of neural cell populations, is broadly expressed in mouse models of SHH MB. ChIP-Seq of Olig2 revealed its binding to a large number of sites near genes known to promote SHH MB tumorigenesis, suggesting a potential role for Olig2 in regulating transcriptional programme of MB. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - March 23, 2024 Category: Genetics & Stem Cells Tags: Genome binding/occupancy profiling by high throughput sequencing Mus musculus Source Type: research
Primary central nervous system tumors survival in children in ten Colombian cities: a VIGICANCER report
CONCLUSION: We found that half of Colombia's children and adolescents with primary CNS tumors survive five years, compared to 70% to 80% in high-income countries. In addition to tumor biology and location, gross total resection was crucial for improved survival in this cohort. Systematic monitoring of survival and its determinants provides empirical data for guiding cancer control policies.PMID:38505512 | PMC:PMC10949889 | DOI:10.3389/fonc.2023.1326788 (Source: Cancer Control)
Source: Cancer Control - March 20, 2024 Category: Cancer & Oncology Authors: Oscar Ramirez Vivian Piedrahita Jesus Ardila Carlos Pardo Edgar Cabrera-Bernal John Lopera Amaranto Suarez Carlos Andr és Portilla Carlos Narv áez Pamela Rodriguez Ximena Castro Ángel Castro Diego Ivan Estupinan-Perico Diana Valencia Mar ía Del Rosari Source Type: research
Cancers, Vol. 16, Pages 1223: Proteomic Profiling of Cerebrospinal Fluid and Its Extracellular Vesicles from Extraventricular Drainage in Pediatric Pilocytic Astrocytoma, towards Precision Oncology
Maurizio Bruschi
Pediatric pilocytic astrocytoma (PA) is the most common brain tumor in children. Complete resection provides a favorable prognosis, except for unresectable PA forms. There is an incomplete understanding of the molecular and cellular pathogenesis of PA. Potential biomarkers for PA patients, especially the non-BRAF-mutated ones are needed. Cerebrospinal fluid (CSF) is a valuable source of brain tumor biomarkers. Extracellular vesicles (EVs), circulating in CSF, express valuable disease targets. These can be isolated from CSF from waste extraventricular drainage (EVD). We analyzed the proteome of EVD C...
Source: Cancers - March 20, 2024 Category: Cancer & Oncology Authors: Sonia Spinelli Xhuliana Kajana Andrea Garbarino Martina Bartolucci Andrea Petretto Marco Pavanello Enrico Verrina Giovanni Candiano Isabella Panfoli Maurizio Bruschi Tags: Article Source Type: research
Effects of cognitive-motor intervention for pediatric posterior fossa tumor survivors: results of a pilot study
AbstractThe purpose of this prospective pilot study was to evaluate the feasibility and effects of cognitive-motor intervention on the cognitive and motor abilities of pediatric survivors of posterior fossa tumors. The study involved patients aged 7 to 18 years with cognitive deficits who had completed primary treatment for posterior fossa tumors. 25 participants (Mage=11.3 ± 2.93, 64% male; 17 medulloblastoma, 1 ependymoma, 1 desmoplastic medulloblastoma, 6 piloid astrocytoma; 22 in remission (Mmonths =45), 3 in stabilization (Mmonths=49)) were recruited from the Research Institute for Brain Development and Peak Per...
Source: Journal of Neuro-Oncology - March 15, 2024 Category: Cancer & Oncology Source Type: research
Case report: Turcot syndrome type 2 in a developing country within the Caribbean
We report a case of medulloblastoma of a 12-year-old Indo-Trinidadian female with a strong family history of colorectal carcinoma. In collaboration with the SickKids-Caribbean Initiative (SCI), her tumor was confirmed to be a WHO grade 4 medulloblastoma – Wnt subtype. Genetic testing further confirmed the presence of a pathogenic APC gene variant [c.3183_3187del (p.Gln1062*)] which led to a diagnosis of Turcot syndrome type 2. The index patient received multimodal therapy which included surgery, radiation and chemotherapy and is currently post end-of-treatment and in remission. This case report aims to highlight the comp...
Source: Frontiers in Oncology - March 14, 2024 Category: Cancer & Oncology Source Type: research
